Especially, we show that the induction of PR expression and S118-ERα phosphorylation, two markers of ERα signaling activation, requires a supratherapeutic dose of E4 to achieve the same effect as the therapeutic dose of E2 in breast cancer cells in vitro and in vivo. The gene discussed is ESR1; the disease is breast cancer.